Compte de Résultat Prévisionnel: Gland Pharma Limited

Forecast Balance Sheet: Gland Pharma Limited

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - -30,018 -30,896 -37,674 -15,197 -21,039 -29,313
Change - - 2.92% 21.94% -59.66% -17.09% 39.33%
Announcement Date 7/10/20 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR in Million
Estimates

Cash Flow Forecast: Gland Pharma Limited

Fiscal Period: March 2021 2022 2023 2024 2025 2026
CAPEX 1 2,288 5,113 2,209 3,899 4,668 3,286
Change - 123.51% -56.79% 76.5% -51.19% -29.59%
Free Cash Flow (FCF) 1 3,762 2,800 1,430 6,069 -1,776 6,564
Change - -25.57% -48.91% 324.27% -84.3% -469.66%
Announcement Date 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR in Million
Estimates

Forecast Financial Ratios: Gland Pharma Limited

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026

Profitability

       
EBITDA Margin (%) - 37.61% 34.32% 28.27% 23.53% 25.67% 26.25%
EBIT Margin (%) - 34.75% 31.81% 24.22% 17.45% 20.74% 20.91%
EBT Margin (%) - 38.55% 36.78% 29.1% 19.99% 23.84% 22.67%
Net margin (%) - 28.79% 27.53% 21.55% 13.64% 16.97% 17.54%
FCF / Net Income (%) - 10.86% 6.36% 3.95% 10.71% -2.84% 9.26%

Profitability

       
ROA - 18.84% 16.91% 9.4% 7.95% 9.84% 10.2%
ROE - 20.88% 18.55% 10.33% 9.26% 11.04% 11.29%

Financial Health

       
Leverage (Debt/EBITDA) - - - - - - -
Debt / Free cash flow - - - - - - -

Capital Intensity

       
CAPEX / Current Assets (%) - 6.61% 11.62% 6.1% 6.88% 7.46% 4.64%
CAPEX / EBITDA (%) - 17.57% 33.86% 21.56% 29.25% 29.05% 17.66%
CAPEX / FCF (%) - 60.82% 182.64% 154.45% 64.25% -262.86% 50.07%

Items per share

       
Cash flow per share 1 - - - 22.1 60.51 61.77 -
Change - - - - 173.81% 161% -
Dividend per Share 1 - - - - 20 4.25 2.333
Change - - - - - 182.14% 54.9%
Book Value Per Share 1 - 381 437.6 483.2 529.6 599.6 650.5
Change - - 14.85% 10.44% 9.61% 111.09% 108.48%
EPS 1 - 62.99 73.64 47.43 46.89 64.62 74.89
Change - - 16.91% -35.59% -1.14% 117.62% 115.89%
Nbr of stocks (in thousands) - 163,593 164,303 164,701 164,752 164,752 164,752
Announcement Date - 5/17/21 5/19/22 5/18/23 5/22/24 - -
1INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
1,994.75INR
Average target price
1,869.08INR
Spread / Average Target
-6.30%
Consensus
  1. Stock Market
  2. Equities
  3. GLAND Stock
  4. Financials Gland Pharma Limited